Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Golimumab Administered Subcutaneously in Subjects With Active Axial Spondyloarthritis (Protocol No. P07642, Also Known as MK-8259-006-02)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms GO-AHEAD
- Sponsors Merck & Co; Merck Sharp & Dohme
- 20 Apr 2021 Results (n=189) from open label extension of the GO-AHEAD study evaluating the long term efficacy and safety of golimumab in patients with axial spondyloarthritis, published in the Rheumatology
- 26 Jun 2015 According to an MSD media release, the European Commission approved SIMPONI (golimumab) following the positive opinion of the CHMP for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA) based on the findings from this GO-AHEAD study.
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.